EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Translational lung cancer research（2023）
摘要
The approvals of mobocertinib, amivantamab, and trastuzumab deruxtecan represent the first examples of precision oncology for exon 20 insertion-mutated and -mutated NSCLCs.
更多查看译文
关键词
EGFR,ERBB2,mobocertinib,amivantamab,trastuzumab deruxtecan
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要